GSK up 1.13% after share buybacks and strong technical signals

Traders Union
All News
Financial News
GSK rises 1.13% today above GBX 1,830

Highlights

GSK repurchased 203,000 ordinary shares at an average price of 1,800.44 pence per share as part of its ongoing £2 billion buyback program.
Since September 2025, GSK has bought back over 11.3 million shares, increasing treasury share holdings to about 236.8 million, representing 5.81% of issued share capital.
The share buyback aims to optimize GSK’s capital structure and enhance shareholder value while continuing its regular dividend program.

Share buybacks accelerate as GSK pursues capital structure optimization

GSK is actively executing its ongoing £2 billion share buyback program, recently repurchasing 203,000 ordinary shares at an average price of 1,800.44 pence per share. Since September 2025, the company has bought back over 11.3 million shares, growing treasury share holdings to approximately 236.8 million — about 5.81% of issued share capital. This effort aims to optimize GSK’s capital structure and enhance shareholder value while the regular dividend program continues.

Strong technical momentum amid emerging overbought signals and key supports

Momentum indicators remain strong, with MACD and ADX signaling buy conditions. RSI is in bullish territory at 63.73 without clear overbought stress, though Stochastic RSI and BBP point to increasing buyer dominance and some overbought conditions on higher timeframes. CCI is also supportive of further gains, while the Awesome Oscillator shows a neutral bias. The nearest dynamic support is the Ichimoku Kijun at GBX 1,727.25, while resistance is now seen near recent highs and the psychological level of GBX 1,850.

Consolidation likely with bullish bias unless support levels are breached

For the coming five trading days, the expected price range is GBX 1,810 to GBX 1,950, reflecting the ongoing bullish trend and typical volatility. The probability of further gains is very high (more than 80%), while a reversal is much less likely. In the baseline scenario, prices may consolidate sideways in a corridor above key supports, while a move above GBX 1,850 could target the GBX 1,900 – 1,950 zone. Any bearish move would be triggered by a break below GBX 1,810, exposing dynamic support near GBX 1,730.

Anton Kharitonov, expert at Traders Union, sees GSK’s technical outlook as bullish but cautions that several overbought signals are emerging on higher timeframes. He notes that the ongoing share buyback program and resilient momentum indicators support the price, yet warns the upside could be limited if GBX 1,850 fails to break. The analyst believes the probability of further gains is high, but a failure at support around GBX 1,810 would threaten the trend. "The base case is consolidation above key supports — but I remain cautious until price convincingly clears the GBX 1,850 resistance zone."

Previously it was reported that GSK traded above all key moving averages, while technical momentum indicators such as MACD and ADX signaled robust buying interest alongside a constructive but not overbought RSI. Near-term resistance was seen at the MA-50 and the round level at GBX 1,850.00, with dynamic support anchored by the Ichimoku Kijun as the probability of further gains remained elevated.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.